Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences.

Détails

ID Serval
serval:BIB_F792F8B6CFA0
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences.
Périodique
International Journal of Neuropsychopharmacology
Auteur(s)
Bondolfi G., Lissner C., Kosel M., Eap C.B., Baumann P.
ISSN
1461-1457
Statut éditorial
Publié
Date de publication
2000
Peer-reviewed
Oui
Volume
3
Numéro
1
Pages
55-60
Langue
anglais
Résumé
In an open trial 11 in-patients with a major depressive episode (ICD-10), extensive metabolizers of mephenytoin (CYP2C19) and dextromethorphan (CYP2D6) and who were non-responders to a 3-wk pretreatment with 40 mg/d citalopram (Cit), were co-medicated for 7 wk (days 0-49) with fluoxetine (Fluox) (10 mg/d). Plasma concentrations of S-Cit and R-Cit significantly increased from day 0 (means+/-S.D.: 28+/-9 and 47+/-11 &mgr;g/l, respectively) to day 49 (58+/-12 and 72+/-21 &mgr;g/l, respectively) (p & 0.01 for each comparison), and the S-Cit/R-Cit ratio increased from 0.61+/-0.16 to 0.82+/-0.12 (p & 0.01). Therefore, Fluox increases the pharmacologically more active S-Cit (in comparison with R-Cit) with some stereoselectivity, most probably by inhibition of CYP2D6 and CYP3A4. Eight of the 11 patients showed clinical improvement (reduction > 50% of the MADRS score) and the combined treatment was generally well tolerated.
Pubmed
Web of science
Open Access
Oui
Création de la notice
10/03/2008 11:38
Dernière modification de la notice
09/05/2019 3:38
Données d'usage